5 High Growth Healthcare Stocks to Buy Now

2. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, reiterating an Outperform rating on the shares and telling investors in a research note that the primary catalyst for the company this year is Pfizer’s tafamidis litigation bench trial from April 27 to May 5, which holds the potential to materially impact the stock. The firm added that it raised the price target based on factors such as the continued strength of Attruby, updated infigratinib data in achondroplasia and hypochondroplasia, and the potential upside from a favorable litigation outcome, which can add considerable value per $1 billion in peak sales.

In another development, BridgeBio Pharma, Inc. (NASDAQ:BBIO) was initiated with an Outperform rating on March 10 by William Blair, with a fair value estimate of $93.03 per share. The firm told investors in a research note that the company is a commercial-stage biotech in a “unique position”, with an accelerating launch in Attruby, regulatory submission for infigratinib in achondroplasia planned for the second half of 2026, and near-term new drug application submissions setting up late-2026 or early-2027 launches. Blair added that it sees Attruby to be well positioned for growth.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company that discovers, creates, tests, and delivers transformative medicines to treat patients suffering from genetic diseases and cancers.